Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01229644 · ClinicalTrials.gov registry record · Phase 2
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
A Phase 2 study, sponsored by Arog Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01229644: Clinical Trial Phase 2 study, sponsored by Arog Pharmaceuticals.
NCT01229644 is a Phase 2 study that was terminated before completion, run by Arog Pharmaceuticals. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01229644, a Phase 2 study, was terminated before completion, sponsored by Arog Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the antitumor efficacy of crenolanib (CP-868,596) in patients with recurrent high grade glioma and in patients with low grade glioma.
Interventions
- DRUG Crenolanib (CP-868,596)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Why NCT01229644 stopped before completion
NCT01229644 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Crenolanib (CP-868,596) is the first listed.
NCT01229644 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01229644 about?
NCT01229644 is a clinical study titled "Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas". The purpose of this study is to evaluate the antitumor efficacy of crenolanib (CP-868,596) in patients with recurrent high grade glioma and in patients with low grade glioma.
What is the current status of trial NCT01229644?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2011-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01229644?
The interventions under investigation include: Crenolanib (CP-868,596) (DRUG).
Who is sponsoring clinical trial NCT01229644?
This trial is sponsored by Arog Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01229644's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia